Peanut oral immunotherapy successfully desensitized children and adolescents allergic to peanuts, reported a phase 3 trial in the New England Journal of Medicine.
At baseline, all 555 eligible trial participants (mostly aged 4 to 17 years) were highly peanut allergic, unable to tolerate more than one-tenth of a peanut kernel. These individuals were randomly assigned to receive escalating doses of a peanut-derived investigational biologic oral immunotherapy (AR101) or placebo. Participants who successfully consumed 300 mg per day of AR101 for approximately 24 weeks underwent a placebo-controlled food challenge at the end of the study.
Slomski A. Immunotherapy for Peanut Allergy Shows Promise. JAMA. 2019;321(4):335. doi:10.1001/jama.2018.21064
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: